ClinConnect ClinConnect Logo
Search / Trial NCT06686329

Physical Activity to Prevent and Treat Hyperglycemia from a Mistimed Bolus Insulin Dose

Launched by JANE YARDLEY · Nov 11, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Type 1 Diabetes Exercise Hyperglycemia

ClinConnect Summary

This clinical trial is studying how combining a walk with a post-meal insulin dose can help manage high blood sugar levels in adults with type 1 diabetes. Sometimes, people forget to take their insulin before meals, which can lead to a rise in blood sugar. The researchers want to see if doing 15 minutes of brisk walking after taking the insulin can help lower blood sugar levels and prevent hyperglycemia, which is when blood sugar gets too high.

To participate in this study, you need to be between 18 and 24 years old and have been diagnosed with type 1 diabetes for at least two years. You should also be using a specific continuous glucose monitor (Dexcom G7) to track your blood sugar. Participants will be monitored while they try this walking and insulin approach, and the trial is currently looking for volunteers. It's important to note that individuals with certain health conditions or those who have recently changed their insulin treatment may not be eligible to join.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults aged 18-24 years
  • Type 1 diabetes diagnostic for at least two years
  • Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9%
  • Use a Dexcom G7 CGM in routine care
  • Exclusion Criteria:
  • Changes in insulin management strategy within the past 2 months
  • Diagnosis of gastroparesis
  • Having a condition that could render exercise harmful
  • Intolerance to gluten and lactose
  • Having significant renal disease (e.g., eGRF \< 30 ml/min)
  • Inability to provide informed consent due to cognitive deficit
  • Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable for more than three months
  • For women, being pregnant or breastfeeding

About Jane Yardley

Jane Yardley is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a commitment to ethical standards and rigorous scientific methodologies, Jane Yardley collaborates with leading researchers and healthcare professionals to design and implement clinical trials that address unmet medical needs. By fostering a culture of transparency and collaboration, the organization strives to accelerate the development of safe and effective treatments, ultimately enhancing the quality of care for patients worldwide.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported